Finance

Beta
Lists
BEAM:BMV
Beam Therapeutics Inc
MX$547.00
-3.12%
(-17.61) 1D
Jun 5, 2:00:00 PM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for BEAM...
Open
MX$547.00
High
MX$547.00
Low
MX$547.00
Mkt. cap
3.02B
Avg. vol.
9.00
Volume
18.00
52-wk high
MX$630.89
52-wk low
MX$300.57
No. of employees
522
Open
MX$547.00
High
MX$547.00
Low
MX$547.00
Mkt. cap
3.02B
Avg. vol.
9.00
Volume
18.00
52-wk high
MX$630.89
52-wk low
MX$300.57
No. of employees
522
News stories
From sources across the web
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc
CEOJohn Evans
Employees522
Founded2017
Headquarters-
SectorBiotechnology
Websitebeamtx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
8.47M
9.70M
114.11M
31.74M
Cost of goods sold
101.76M
109.77M
99.28M
11.06M
Cost of revenue
101.76M
109.77M
99.28M
11.06M
Research and development expenses
-
-
-
93.47M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.86M
26.74M
32.28M
34.43M
Operating expense
26.86M
26.74M
32.28M
127.90M
Total operating expenses
128.62M
136.51M
131.55M
138.95M
Operating income
-120.15M
-126.81M
-17.44M
-107.22M
Other non operating income
1.15M
8.55M
50.00K
2.50M
EBT including unusual items
-102.29M
-112.73M
244.30M
-94.32M
EBT excluding unusual items
-106.68M
-118.26M
248.39M
-94.85M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-102.29M
-112.73M
244.30M
-94.32M
Net profit margin
-1,208.26%
-1,162.38%
214.09%
-297.18%
Earnings per share
-1.00
-1.10
2.33
-0.91
Interest and investment income
12.33M
-
10.64M
9.87M
Interest expense
-
-
-
-
Net interest expenses
12.33M
-
10.64M
9.87M
Depreciation and amortization charges
-
-
-
-
EBITDA
-114.61M
-121.25M
-11.78M
-101.61M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer